We provide you with 20 years of free, institutional-grade data for VRDN stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of VRDN. Explore the full financial landscape of VRDN stock.
| Reported Date | CIK | Ticker | Type |
|---|
Viridian Therapeutics, Inc.(NASDAQ:VRDN) 
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody for the treatment of thyroid eye disease; VRDN-002, a biosuperior IGF-1R antibody; and VRDN-003, an IGF-1R antibod...
Share this website to your friends
The information provided in this report about VRDN stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.